This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Mar 2011

Genentech aBCC Drug Meets Phase II Endpoint

Genentech announced positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma.

Genentech, a member of the Roche Group, announced yesterday that the Phase II study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), achieved positive results in people with advanced basal cell carcinoma (aBCC), a severe form of skin cancer.
 
The study met its primary endpoint, showing vismodegib shrank tumors in a pre-defined percentage of people in the study. A preliminary safety assessment showed the most common adverse events were consistent with previous vismodegib studies.

"These results are important because people with this disfiguring and potentially life-threatening a

Related News